HLA-B27 - Normal Range, Markers & Result Interpretation

HLA-B27 is a class I antigen of the major histocompatibility complex; its presence is tested in the diagnostic workup of autoimmune diseases such as ankylosing spondylitis or sacroiliitis. Understanding the reference values, indicators, and skilled interpretation of HLA-B27 test results is critical for clinicians when assessing the risk of these conditions and planning further treatment. In this article we explain what the presence of HLA-B27 means, how to read the result, and its clinical relevance.

How to interpret your positive or negative result

An HLA-B27 result is reported as positive or negative — there is no numeric reference range. The lab is checking whether the HLA-B27 protein is present on the surface of your white blood cells, where it normally helps the immune system tell self-tissue from foreign material.

A negative result means the HLA-B27 antigen is absent. That lowers the probability that joint or back symptoms are driven by ankylosing spondylitis or another spondyloarthritis, but it does not fully rule them out. Some people develop ankylosing spondylitis without carrying the gene variant, which is why a negative result is interpreted alongside imaging, inflammatory markers, and clinical history.

A positive result means the antigen is present. It signals a higher-than-average genetic susceptibility to a family of inflammatory conditions known collectively as spondyloarthritis. It is not a diagnosis. In the United States, roughly 6 to 8 percent of the population carries HLA-B27, and the vast majority never develop an HLA-B27 associated syndrome. The allele contributes only about 25 to 30 percent of the genetic risk for ankylosing spondylitis — the rest comes from more than a hundred other genetic loci plus environmental factors.

How clinicians combine the result with other findings

HLA-B27 is rarely interpreted in isolation. A rheumatologist typically combines it with:

The presence or absence of HLA-B27 is one probability input among many. It raises or lowers the likelihood of spondyloarthritis when symptoms are already suspicious, but on its own it is not enough to confirm or exclude the diagnosis.

Diseases linked to a positive HLA-B27 result

A positive HLA-B27 is associated with a cluster of inflammatory conditions collectively called spondyloarthritis. The strength of the link varies sharply depending on the specific condition.

The spondyloarthritis family covered by HLA-B27 testing includes:

• Ankylosing spondylitis (AS) — the prototype condition; HLA-B27 is present in roughly 90 percent of patients with AS in white populations
• Acute anterior uveitis — a painful inflammation of the front of the eye; meta-analyses report HLA-B27 positivity in 40 to 82.5 percent of cases, and uveitis can precede AS by about three years
• Reactive arthritis — joint inflammation triggered by an infection (commonly Campylobacter, Shigella, Yersinia, Salmonella, Clostridium difficile, or Chlamydia trachomatis); HLA-B27 carriers face markedly higher risk than the general population
• Psoriatic arthritis — HLA-B27 is found in fewer than half of patients
• Arthritis associated with inflammatory bowel disease (Crohn disease or ulcerative colitis) — also under 50 percent positivity
• Sacroiliitis — inflammation of the sacroiliac joints, the structural hallmark of axial spondyloarthritis

What the percentages actually mean

A high positivity rate in a disease group (such as ~90 percent in AS) does not mean a positive test diagnoses the disease. It means that among people who already have AS, most carry the antigen — useful when assembling a probability picture but not a stand-alone diagnostic. Conversely, a positive HLA-B27 in someone with no inflammatory symptoms carries only a 1 to 2 percent lifetime risk of developing ankylosing spondylitis. That figure rises to roughly 20 percent if the person has a first-degree relative with AS.

The mechanism linking HLA-B27 to these conditions is still being worked out. The leading hypothesis — the arthritogenic peptide hypothesis — proposes that HLA-B27 presents certain microbial peptides to immune cells in a way that triggers a cross-reactive response against the body’s own tissues. Misfolding of the HLA-B27 protein inside cells is one alternative explanation.

HLA-B27 and ankylosing spondylitis: what a positive gene actually means

Ankylosing spondylitis is the condition most strongly tied to HLA-B27, and most user questions about a positive result trace back to AS. A positive result in someone with inflammatory back pain raises the pre-test probability substantially, but the diagnostic pathway still rests on imaging and clinical features.

How AS is diagnosed in practice

Ankylosing spondylitis is hard to diagnose because it develops slowly and there is no single confirmatory test. A GP who suspects AS typically:

1. Asks about symptom pattern — particularly inflammatory back pain that does not improve with rest and may wake you at night
2. Orders blood tests for inflammation
3. Refers to a rheumatologist for imaging (X-ray, MRI, or ultrasound) and further blood work, which may include genetic testing for HLA-B27

A diagnosis of AS is usually confirmed when an X-ray shows inflammation of the sacroiliac joints (sacroiliitis) together with clinical features such as at least three months of lower back pain that improves with exercise but not rest, limited lumbar movement, or limited chest expansion.

When the X-ray is normal

If an X-ray cannot confirm AS, an MRI is usually offered next. MRI evidence of sacroiliac inflammation supports a diagnosis of non-radiographic axial spondyloarthritis — the same disease family at an earlier stage. When neither X-ray nor MRI shows inflammation, a diagnosis of non-radiographic axial spondyloarthritis may still be made in someone who carries the HLA-B27 gene variant and has consistent symptoms. This is the clearest example of HLA-B27 acting as a diagnostic input rather than a stand-alone result.

The reverse case is equally important: AS can occur in people who do not carry HLA-B27. The gene variant explains only about 25 to 30 percent of the heritability of AS, and roughly 10 to 40 percent of AS patients (depending on the population studied) test negative.

How common HLA-B27 is and who carries it

Base rates matter when interpreting a positive result. HLA-B27 is far more common than the diseases it is linked to, which is why most carriers never develop one.

Prevalence by region and ancestry

Sources:.

The geographic gradient — higher at northern latitudes — tracks with the global distribution of ankylosing spondylitis, which is also more common where HLA-B27 is more common. Among African American patients with AS, fewer than 60 percent carry HLA-B27, compared with about 90 percent in white populations.

Subtypes: more than 100 versions of the gene

HLA-B27 is not a single uniform variant. More than 100 subtypes have been characterized, and over 200 alleles are now described at the nucleotide level. Standard clinical HLA-B27 testing reports the gene as present or absent and does not break out which subtype you carry. A few subtypes — notably B*2706 and B*2709 — are not associated with ankylosing spondylitis at all. The most common disease-associated subtypes are B2705 in white and American Indian populations, B2702 in Mediterranean populations, and B*2704 in Asian populations.

This subtype variability helps explain why HLA-B27 positivity carries different clinical weight in different populations, and why a positive result is interpreted in context rather than in isolation.

Why most carriers stay healthy

The most reassuring number for someone with a new positive result is the lifetime risk: only about 1 to 2 percent of HLA-B27 positive people develop ankylosing spondylitis. Even with a first-degree relative who has AS, the lifetime risk rises only to about 20 percent — meaning four out of five carriers in that higher-risk group still do not develop the disease. HLA-B27 has also been associated with a protective effect against some viral infections, including HIV and hepatitis C.

Frequently asked questions

Is a positive HLA-B27 result dangerous?

A positive HLA-B27 result is not itself a disease and is not dangerous on its own. It identifies an inherited susceptibility, not an active condition. About 6 to 8 percent of people in the United States carry HLA-B27, and the vast majority never develop an HLA-B27 associated syndrome. The lifetime risk of ankylosing spondylitis for a carrier is roughly 1 to 2 percent.

Can you have ankylosing spondylitis without HLA-B27?

Yes. HLA-B27 is found in most people with ankylosing spondylitis but not all of them, and the gene variant explains only about 25 to 30 percent of the genetic risk for AS. A negative HLA-B27 test does not rule out AS, particularly in the early or non-radiographic stages, and diagnosis still rests on imaging and clinical features.

Is HLA-B27 linked to cancer?

No. HLA-B27 is a susceptibility marker for inflammatory autoimmune conditions such as ankylosing spondylitis, acute anterior uveitis, reactive arthritis, psoriatic arthritis, and arthritis associated with inflammatory bowel disease — not for cancer. HLA-B27 testing is not used as a cancer screen.

What is the HLA-B27 antigen?

HLA-B27 (human leukocyte antigen B27) is a class I MHC protein found on the surface of nearly all nucleated cells. Its normal function is to present small peptide fragments to immune cells called CD8 T cells, which use this signal to identify infected or abnormal cells. It is made from instructions in an inherited gene on chromosome 6.

What does HLA-B27 positive mean for women?

The clinical meaning of a positive result is the same in women and men, but recognition of ankylosing spondylitis has historically been more difficult in women. Recent advances in detecting non-radiographic axial spondyloarthritis have challenged the older view that AS is predominantly a male disease. Disease onset for axial spondyloarthritis is typically between 20 and 40 years of age in both sexes.

Does a negative HLA-B27 rule out spondyloarthritis?

No. The gene variant is found in most people with ankylosing spondylitis but is not entirely reliable as a stand-alone test — some patients have the condition without the variant, and others carry the variant without developing AS. Diagnosis depends on the full clinical picture, including imaging of the spine and sacroiliac joints and markers of inflammation.

Should I see a specialist after a positive result?

A positive HLA-B27 on its own does not require specialist care. If you also have inflammatory back pain, eye redness or pain, joint swelling, psoriasis, or symptoms of inflammatory bowel disease, your clinician will typically refer you to a rheumatologist for evaluation.

When to talk to your doctor

A positive HLA-B27 result is not itself a reason for alarm, but specific symptom patterns warrant medical evaluation — particularly because the conditions in the spondyloarthritis family respond better when caught early. Talk to a clinician if you experience any of the following:

• Inflammatory back pain — back or buttock pain that started before age 45, came on gradually over more than three months, is worse at night (especially in the second half of the night), improves with exercise, and does not improve with rest
• Sudden eye redness and pain — acute onset of unilateral red eye with pain, light sensitivity, or blurred vision, which can signal acute anterior uveitis and needs prompt ophthalmologic evaluation
• Joint swelling, dactylitis, or heel pain — persistent peripheral joint swelling, sausage-like swelling of a finger or toe (dactylitis), or pain at tendon insertion points such as the heel (enthesitis)
• Joint symptoms after a recent infection — sudden joint pain in the 1 to 4 weeks after a genitourinary or gastrointestinal infection may suggest reactive arthritis
• Joint or back symptoms with psoriasis, bowel inflammation, or a family history of spondyloarthritis — clusters of features across skin, gut, and joints raise the clinical suspicion of spondyloarthritis
• Changes in bowel habits or blood in the stool alongside joint symptoms, which may point to inflammatory bowel disease–associated arthritis

If a GP suspects spondyloarthritis, they will typically arrange blood tests for inflammation and refer you to a rheumatologist for imaging and further evaluation. Diagnosis can take time and may involve repeat assessments as symptoms evolve.

References

• MedlinePlus — HLA-B27 antigen
• NHS — Ankylosing spondylitis: diagnosis
• NCBI Bookshelf (NBK551523) — HLA-B27 Syndromes
• PubMed Central (PMC10476136) — HLA-B27 and ankylosing spondylitis review

Last reviewed: 2026-05-17